Table of Contents
Published: July 8, 2025
Read Time: 4 Mins
Total Views: 153
Dr. Jay Varma explains how lenacapavir, a twice-yearly injection, could revolutionize HIV prevention by overcoming adherence barriers and expanding access to care—if health systems adapt to deliver it equitably.
A New Era in HIV Prevention
For over four decades, the world has grappled with the devastating impact of HIV/AIDS. While prevention and treatment advances have been extraordinary, nearly 30,000 Americans are still newly infected each year. Despite HIV now being entirely preventable and treatable, the epidemic persists, especially in marginalized communities.
The U.S. Food and Drug Administration’s approval of lenacapavir in June 2025 marks one of the most significant breakthroughs since the advent of pre-exposure prophylaxis (PrEP). Unlike daily oral medications, lenacapavir requires just two injections a year—making prevention far more feasible for people who struggle with daily adherence or consistent healthcare access.
How HIV Prevention Has Evolved
From the 1980s until the early 2010s, prevention focused on two pillars: behavioral change (reducing high-risk practices) and barrier methods (such as condoms). These slowed transmission but were not enough to end the epidemic.
The tide shifted in 2010, when landmark studies proved that antiretroviral medications could be used not only for treatment but also for prevention. This included oral PrEP for HIV-negative individuals and U=U (Undetectable = Untransmittable), showing that effective treatment makes HIV untransmittable. These discoveries changed policy and practice worldwide, with PrEP earning an “A” grade recommendation from the U.S. Preventive Services Task Force in 2019, requiring insurance coverage.
Yet daily oral PrEP comes with challenges: insurance requirements, quarterly testing, and strict adherence. Many at highest risk—such as gay and bisexual men, transgender women, and people in the South or communities of color—continue to face barriers to access.
Why Lenacapavir Could Be Transformative
Lenacapavir targets the HIV capsid—the protein shell around the virus’s genetic material. Its unique pharmacology allows for long-acting protection, with a subcutaneous injection lasting at least six months.
Clinical trials have delivered striking results:
- PURPOSE 1 (2024): Involving more than 5,300 adolescent girls and young women in South Africa and Uganda, the trial reported zero infections among those receiving lenacapavir, compared to dozens in oral PrEP groups.
- PURPOSE 2: Extending to cisgender men, transgender women, and nonbinary individuals who have sex with men, the trial showed a 96% reduction in HIV incidence compared to background infection rates.
These outcomes are unparalleled in HIV prevention research, suggesting that lenacapavir could function almost like a “biomedical vaccine” against HIV.
“Science has given us the tools to end the HIV epidemic. The real test is whether our health systems can deliver them to everyone who needs them.” —Dr. Jay Varma
Challenges Ahead
While promising, lenacapavir is not without hurdles.
Individual risks:
- Injection site reactions were common but mild.
- Missed or delayed doses can create a “pharmacologic tail,” where drug levels are too low for protection but high enough to encourage drug resistance.
System-level challenges:
- Clinics must build infrastructure for regular injections.
- Reminder systems are needed to ensure patients don’t miss doses.
- Surveillance for drug resistance must be strengthened.
- Funding pressures from Medicaid and health program cuts could limit access for the very populations most at risk.
Without equitable access, this breakthrough risks reinforcing disparities instead of closing them.
Should You Consider Lenacapavir?
For individuals with multiple sexual partners or others at heightened risk, lenacapavir presents a compelling new option. Twice-yearly injections reduce the burden of daily medication and may increase adherence across diverse populations.
Even more promising, early data suggest that once-yearly injections could become possible, with new Phase III trials beginning later this year.
The critical question is not whether science can prevent HIV—it can—but whether society and health systems can ensure that prevention reaches everyone who needs it.
Lenacapavir offers a monumental leap forward in HIV prevention. But its success depends on how well healthcare systems can deliver it equitably, particularly to those communities most impacted by HIV. The science is clear: the tools to end the epidemic exist. The challenge is whether we have the will to use them fairly.
📅 Publication Date & Outlet
July 8, 2025 | Psychology Today
